Advanced Cancer Therapeutics (ACT) advances novel anti-cancer therapeutics discovered at the University of Louisville’s James Graham Brown Cancer Center under exclusive worldwide licenses. Under preset business terms with the Center, ACT selects discoveries and manages their development, commercialization and manufacture for the pharmaceutical industry. Its top programs include novel small-molecule inhibitors targeting PFKFB3 and Choline Kinase. The company is also advancing PU27, a sequence-specific DNA oligonucleotide that inhibits cancer cell proliferation and appeared well tolerated in a preliminary animal toxicology study. ACT recently raised capital to continue the development and commercialization of these therapeutic candidates. The company is based in Louisville, Kentucky. Advanced Cancer Therapeutics (ACT) focuses on developing anti-cancer therapies with the stated goal of bringing those treatments to market. The company operates as a for-profit private entity and began operations in October 2007. ACT is based in Louisville, Ky., and has progressed through early milestones since its founding. Financially, it received a final $250,000 investment from Commonwealth Seed Capital (CSC) ahead of schedule due to achieved progress and milestones. That payment brings CSC’s total investment in ACT to $500,000. CSC is an entity established by the Kentucky Economic Development Partnership Board to invest in seed-stage technology companies in Kentucky.

Total raised

$10M

Funding rounds

3

Latest round

Equity

Latest activity

Jul 2010